As a result, we perform this systematic review and meta-analysis to assess whether the dual anti-HER2 treatment would increase the risk of severe (grade 3 and 4) toxicities of special interest in breast cancer when compared to anti-HER2 monotherapy. This evidence concerns the gene ERBB2 and breast carcinoma.